Tuesday, March 3, 2026 3/3/2026

Regulation of enteric norovirus infection by host-derived and microbiota-transformed bile acids

Award Number: R56AI141478
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 11/25/2018
PERIOD OF PERFORMANCE END DATE: 07/31/2025

Group Awards By:

View Award Description

Regulation of enteric norovirus infection by host-derived and microbiota-transformed bile acids - PROJECT SUMMARY Noroviruses are the leading global cause of acute gastroenteritis, responsible for 685 million total cases, 200 million pediatric cases, and up to 200,000 deaths in children annually. The long-term goal of this research project is to define the mechanisms by which intestinal microbiota influence norovirus pathogenesis and host immunity, and thus identify critical targets for novel therapeutics. Bile acids are a class of metabolites regulated by microbiota that play opposing roles in norovirus infections: Host-derived bile acids promote human and murine norovirus infections whereas microbiota-derived bile acids inhibit infection. Considering that neonates are more susceptible to norovirus infections and they have a distinct bile acid pool compared to adults that is dominated by host-derived (proviral) species, our central hypothesis is that altered homeostatic bile acid metabolism is the central determinant of the increased vulnerability of neonates to norovirus disease. This will be tested by pursuing three specific aims: 1) Test the effect of perturbing the neonatal bile acid pool on norovirus disease; 2) Determine the mechanism by which microbiota- metabolized bile acids protect neonates from norovirus disease; and 3) Determine the role of maternal breast milk bile acids in regulating neonatal susceptibility to norovirus diarrhea. The proposed research is significant because it will provide mechanistic insight into the role of bile acid metabolism in norovirus pathogenesis and test therapeutic strategies to reduce disease severity in infected infants based on this insight. Our studies will also explore the innovative concept that maternal gut metabolites delivered to neonates via breastfeeding determine neonatal susceptibility to norovirus diarrhea, laying the groundwork for developing novel infant-specific therapeutics that target the entero-mammary pathway in the lactating mother. Finally, bile acids are being increasingly recognized as contributing to other pathologic conditions so understanding basic aspects of their metabolism and trafficking in the mammalian host has broad applicability.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $642,669 )
2024	2024	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Allergy and Infectious Diseases Research	001	6	9/13/2024	COMPETING CONTINUATION	$64,267
2024	2024	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Allergy and Infectious Diseases Research	000	6	8/2/2024	COMPETING CONTINUATION	$578,402
														Subtotal = $642,669

Grand Total All Awards = $642,669

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Regulation of enteric norovirus infection by host-derived and microbiota-transformed bile acids

Award Number: R56AI141478

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 11/25/2018

PERIOD OF PERFORMANCE END DATE: 07/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer